| ironjustice@aol.com 2005-04-05, 6:13 pm |
| In Vivo. 2005 Jan-Feb;19(1):233-6. Related Articles, Links
Anti-tumor activities of four chelating agents against human
neuroblastoma cells.
Shen L, Zhao HY, Du J, Wang F.
National Isotope Center of Engineering and Technology, China Institute
of Atomic Energy, Beijing 102413, China. shenlt@yahoo.com
BACKGROUND: Iron deprivation may be a therapeutic strategy for cancer.
It can be achieved by using iron chelators. In this investigation,
anti-neuroblastoma activities of a novel ferric chelator 2LL together
with DFO, EDTA and DTPA were evaluated. MATERIALS AND METHODS: SH-Sy5y
cells were cultured at 37 degrees C in 5% CO2/95% air in DMEM
containing 10% fetal bovine serum. The cells were seeded in 96-well
microtiter plates overnight. Then, chelating agents were added into the
wells. After 48-hour incubation, viabilities were measured using the
MTT method. RESULTS: DTPA had an IC50 value between 60-100 microM; DFO
produced about 40% inhibiting effect at 150 microM; 2LL and EDTA
displayed about 10% inhibiting effect at high concentrations.
CONCLUSION: For SH-Sy5y cells, DTPA showed the strongest inhibiting
effect, DFO displayed a moderate inhibiting effect, while 2LL and EDTA
produced minor inhibition. To develop iron chelators as powerful
anti-cancer agents is still a challenging task.
PMID: 15796180 [PubMed - in process]
--------------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://herbivore.7h.com
|